Joining Savient Pharmaceuticals, Inc. are Maurice Cheeks, long-time gout sufferer and current head coach of the Philadelphia 76ers NBA basketball team; Lawrence Edwards, M.D., Chairman and CEO of the Gout & Uric Acid Education Society; and Ralph Schumacher, M.D., Rheumatologist and a Gout & Uric Acid Education Society Board member.
Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, Puricase(r) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007. Savient has exclusively licensed worldwide rights to the technology related to Puricase from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(r) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
Further information on Savient can be accessed by
visiting: www.savient.com.
| Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search |
